Drug intelligence / Profile preview

NUV001

Development stage: Phase 1
Lead developer: Nuvamid
Administration: Oral

Overview

NUV001 is an investigational orally administered agent being evaluated for its safety, tolerability, and pharmacokinetics in healthy adult participants. It is also being developed as a nutraceutical supplement, available in immediate release (IR) and gastro-resistant (GR) formulations, for the treatment of Sickle Cell Disease. The drug is being developed by Nuvamid SA and LGD.

Other names: NUV001-IRNUV-001-IRNUV 001-IRNUV001-GRNUV-001-GRNUV 001-GR

Beyond the preview

Go deeper on NUV001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NUV001.

Explore the full profile